Efficacy Analysis of 131I Therapy in Serum Thyroglobulin Antibody Positive Differentiated Thyroid Carcinoma with Distant Metastasis

doi:10.12114/j.issn.1007-9572.2023.0705

Abstract

Abstract:

Background

Differentiated thyroid carcinoma (DTC) with distant metastasis generally forecasts a poor prognosis. Timely diagnosis and effective treatment of distant metastasis are pivotal and challenging in clinical practice. Serum thyroglobulin (Tg) is a marker for monitoring tumor residue or recurrence/metastasis post-surgery and post-¹³¹I therapy in DTC. Thyroglobulin antibodies (TgAb) are autoantibodies against Tg that can potentially interfere with Tg measurement. Presently, literature on ¹³¹I treatment of TgAb positive DTC with distant metastasis is sparse.

Objective

To investigate the efficacy of ¹³¹I therapy in TgAb positive DTC with distant metastasis.

Methods

A retrospective analysis was conducted on clinical data of 189 DTC patients treated with ¹³¹I from January 2017 to January 2022 at the People's Hospital of Zhengzhou University. Pre-treatment and follow-up measurements of thyroid-stimulating hormone (TSH), Tg, and TgAb were collected. Patients were categorized into TgAb positive (29 cases) and TgAb negative (160 cases) groups. The efficacy of ¹³¹I therapy was evaluated. Serum thyroid hormones and routine blood tests were conducted 6-8 weeks post-¹³¹I therapy, followed by biannual or annual follow-ups including serum thyroid hormones, Tg, TSH, TgAb, thyroid peroxidase antibodies (TPOAb), neck ultrasound, and CT scans of metastatic sites.

Results

Statistical significance (P<0.05) was observed in the comparison of distant metastatic sites, TPOAb, and pre-first ¹³¹I therapy TgAb levels between the TgAb positive and negative groups. In the TgAb positive group, disease was controlled in 14 patients (48.2%), while 15 patients (51.8%) showed disease progression; in the TgAb negative group, 127 patients (79.4%) showed disease control and 33 patients (20.6%) showed progression. The rate of disease progression in the TgAb positive group was significantly higher than in the TgAb negative group (χ²=7.148, P=0.008) .

Conclusion

The rate of disease progression in serum TgAb positive DTC with distant metastasis is significantly higher than in TgAb negative patients; differences in metastatic sites, TPOAb, and pre-first ¹³¹I therapy TgAb levels were observed between the groups.

Key words: Thyroid neoplasms, Thyroglobulin, Neoplasm metastasis, Anti-thyroid autoantibodies, Clinical effectiveness

摘要：

背景

远处转移分化型甲状腺癌（DTC）的预后较差，及时确诊远处转移并有效治疗是临床诊疗中的重点及难点。血清甲状腺球蛋白（Tg）是DTC术后及¹³¹I治疗后监测肿瘤残留或复发/转移的标志物，甲状腺球蛋白抗体（TgAb）是针对Tg产生的自身抗体，可能对Tg的测定产生干扰。目前有关¹³¹I治疗TgAb阳性远处转移DTC文献报道较少。

目的

探究¹³¹I治疗TgAb阳性DTC伴远处转移的疗效。

方法

回顾性分析2017年1月—2022年1月于郑州大学人民医院接受¹³¹I治疗的189例DTC患者的临床资料。收集患者治疗前及随访中测定促甲状腺激素（TSH）、Tg、TgAb，将患者按照TgAb测定结果分为TgAb阳性组（29例）与TgAb阴性组（160例）。对患者¹³¹I疗效进行评估。¹³¹I治疗后6~8周检测血清甲状腺素及血常规，之后每6~12个月随访血清甲状腺素、Tg、TSH、TgAb、甲状腺过氧化物酶抗体（TPOAb）、颈部超声、转移部位CT等检查结果。

结果

TgAb阳性组与TgAb阴性组患者远处转移部位、TPOAb、首次¹³¹I治疗前TgAb比较，差异有统计学意义（P<0.05）。TgAb阳性组患者中14例（48.2%）疾病控制，15例（51.8%）疾病进展；TgAb阴性组患者127例（79.4%）疾病控制，33例（20.6%）疾病进展。TgAb阳性组疾病进展率明显高于TgAb阴性组（χ²=7.148，P=0.008）。

结论

¹³¹I治疗血清TgAb阳性远处转移DTC疾病进展率明显高于TgAb阴性患者；两组远处转移部位、TPOAb及首次¹³¹I治疗前TgAb存在差异。

关键词: 甲状腺肿瘤, 甲状腺球蛋白, 肿瘤转移, 甲状腺球蛋白抗体, 临床疗效

BAI Xin,WU Xinyu,ZHAO Zun, et al. Efficacy Analysis of ¹³¹I Therapy in Serum Thyroglobulin Antibody Positive Differentiated Thyroid Carcinoma with Distant Metastasis[J]. Chinese General Practice, 2024, 27(15): 1833-1837. DOI: 10.12114/j.issn.1007-9572.2023.0705.
白鑫,武新宇,赵尊等. ¹³¹I治疗血清甲状腺球蛋白抗体阳性分化型甲状腺癌远处转移的疗效研究[J]. 中国全科医学, 2024, 27(15): 1833-1837. DOI: 10.12114/j.issn.1007-9572.2023.0705.

Figures/Tables 1

References 20

[1]	中华医学会核医学分会. ¹³¹I治疗分化型甲状腺癌指南（2021版）[J].中华核医学与分子影像杂志，2021，41(4):218-241. DOI：10.3760/cma.j.cn321828-20201113-00412.
[2]	谢艳，蒋玲，周克华，等. 远处转移分化型甲状腺癌碘难治危险因素及生存分析[J]. 中华内分泌代谢杂志，2017，33(5):387-391. DOI：10.3760/cma.j.issn.1000-6699.2017.05.006.
[3]	HAUGEN B R, ALEXANDER E K, BIBLE K C，et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer：the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid，2016，26(1):1-133. DOI：10.1089/thy.2015.0020.
[4]	SPENCER C A. Clinical utility of thyroglobulin antibody（TgAb）measurements for patients with differentiated thyroid cancers（DTC）[J]. J Clin Endocrinol Metab，2011，96(12):3615-3627. DOI：10.1210/jc.2011-1740.
[5]	EISENHAUER E A, THERASSE P, BOGAERTS J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）[J]. Eur J Cancer，2009，45(2):228-247. DOI：10.1016/j.ejca.2008.10.026.
[6]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗，2021，34(12):1164-1200. DOI：10.3969/j.issn.1674-0904.2021.12.013.
[7]	GIOVANELLA L, MILAN, ROLL W，et al. Postoperative thyroglobulin as a yard-stick for radioiodine therapy：decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging，2023，50(9):2767-2774. DOI：10.1007/s00259-023-06239-8.
[8]	JO K, LIM D J. Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer[J]. Korean J Intern Med，2018，33(6):1050-1057. DOI：10.3904/kjim.2018.289.
[9]	张娜，梁军，林岩松. 甲状腺球蛋白抗体对甲状腺乳头状癌¹³¹I清甲疗效的影响[J]. 中国癌症杂志，2017，27(6):476-481. DOI：10.19401/j.cnki.1007-3639.2017.06.013.
[10]	SPENCER C, PETROVIC I, FATEMI S. Current thyroglobulin autoantibody（TgAb）assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer[J]. J Clin Endocrinol Metab，2011，96(5):1283-1291. DOI：10.1210/jc.2010-2762.
[11]	黄雪梅，王社教，封娟毅. 血清TgAb水平对预测DTC术后转移/复发的临床价值[J]. 现代肿瘤医学，2015，23(11):1515-1517. DOI：10.3969/j.issn.1672-4992.2015.11.11.
[12]	范群，匡安仁，袁耿彪. 血清抗甲状腺球蛋白抗体对分化型甲状腺癌术后复发/转移的诊断价值[J]. 中华内分泌代谢杂志，2007，23(6):494-497. DOI：10.3760/j.issn:1000-6699.2007.06.005.
[13]	KATRANGI W, GREBE S K G, ALGECIRAS-SCHIMNICH A. Analytical and clinical performance of thyroglobulin autoantibody assays in thyroid cancer follow-up[J]. Clin Chem Lab Med，2017，55(12):1987-1994. DOI：10.1515/cclm-2017-0034.
[14]	SPENCER C, FATEMI S. Thyroglobulin antibody（TgAb）methods - Strengths，pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer[J]. Best Pract Res Clin Endocrinol Metab，2013，27(5):701-712. DOI：10.1016/j.beem.2013.07.003.
[15]	祁爱花，柴红. 抗甲状腺球蛋白抗体在甲状腺癌合并结节性甲状腺肿患者中对复发或转移的诊断价值[J]. 标记免疫分析与临床，2022，29(12):2030-2034. DOI：10.11748/bjmy.issn.1006-1703.2022.12.011.
[16]	REVERTER J L, ROSAS-ALLENDE I, PUIG-JOVE C，et al. Prognostic significance of thyroglobulin antibodies in differentiated thyroid cancer[J]. J Thyroid Res，2020，2020:8312628. DOI：10.1155/2020/8312628.
[17]	谢磊，柴凡，鲍刚，等. 血清Tg、TgAb对甲状腺癌根治术联合¹³¹I治疗后随访期间复发/转移的评估价值[J].　中国现代医学杂志，2023，33(19):74-79.
[18]	柴红，陈泽泉，余永利. 抗甲状腺球蛋白抗体增高水平及变化趋势对分化型甲状腺癌转移的预测价值[J]. 中华内分泌代谢杂志，2014，30(4):292-296. DOI：10.3760/cma.j.issn.1000-6699.2014.04.004.
[19]	FELDT-RASMUSSEN U, VERBURG F A, LUSTER M，et al. Thyroglobulin autoantibodies as surrogate biomarkers in the management of patients with differentiated thyroid carcinoma[J]. Curr Med Chem，2014，21(32):3687-3692. DOI：10.2174/0929867321666140826120844.
[20]	TURANLI S, MERSIN H H. Serum antithyroglobulin antibody levels are not a good predictive factor on detection of disease activity in patients with papillary thyroid carcinoma[J]. J Cancer Res Ther，2020，16(3):624-629. DOI：10.4103/jcrt.JCRT_340_17.

组别	例数	性别（男/女）	确诊年龄[M（P₂₅，P₇₅），岁]	病理类型[例（%）]			远处转移部位[例（%）]		转移灶摄碘[例（%）]
组别	例数	性别（男/女）	确诊年龄[M（P₂₅，P₇₅），岁]	PTC	FTC	PTC+FTC	肺	其他部位	是	否
TgAb阳性组	29	9/20	55.0（38.0，58.3）	26（89.7）	3（10.3）	0	18（62.1）	11（37.9）	21（73.4）	8（27.6）
TgAb阴性组	160	51/109	51.0（34.0，59.0）	135（84.4）	24（15.0）	1（0.6）	139（86.9）	21（13.1）	133（83.1）	27（16.9）
χ²（Z）值		0.986	0.143^a	0.706			4.958		0.442
P值		>0.999	0.705	>0.999			0.026		0.506
组别	TPOAb[例（%）]		¹³¹I治疗次数[M（P₂₅，P₇₅），次]	¹³¹I累积剂量[M（P₂₅，P₇₅），mCi]	首次¹³¹I治疗前s-Tg [M（P₂₅，P₇₅），μg/L]	首次¹³¹I治疗前TgAb [M（P₂₅，P₇₅），U/mL]
组别	阳性	阴性	¹³¹I治疗次数[M（P₂₅，P₇₅），次]	¹³¹I累积剂量[M（P₂₅，P₇₅），mCi]	首次¹³¹I治疗前s-Tg [M（P₂₅，P₇₅），μg/L]	首次¹³¹I治疗前TgAb [M（P₂₅，P₇₅），U/mL]
TgAb阳性组	11（37.9）	18（62.1）	2.0（2.0，4.0）	315.0（265.0，712.5）	235.80（27.32，3 960.00）	12.95（8.98，33.18）
TgAb阴性组	22（13.8）	138（86.2）	2.0（2.0，3.0）	300.0（270.0，400.0）	93.88（30.35，418.90）	0.17（0.10，0.20）
χ²（Z）值	4.356		0.005^a	0.023^a	3.277^a	50.502^a
P值	0.037		0.944	0.880	0.070	<0.001

组别	例数	性别（男/女）	确诊年龄[M（P₂₅，P₇₅），岁]	病理类型[例（%）]			远处转移部位[例（%）]		转移灶摄碘[例（%）]
组别	例数	性别（男/女）	确诊年龄[M（P₂₅，P₇₅），岁]	PTC	FTC	PTC+FTC	肺	其他部位	是	否
TgAb阳性组	29	9/20	55.0（38.0，58.3）	26（89.7）	3（10.3）	0	18（62.1）	11（37.9）	21（73.4）	8（27.6）
TgAb阴性组	160	51/109	51.0（34.0，59.0）	135（84.4）	24（15.0）	1（0.6）	139（86.9）	21（13.1）	133（83.1）	27（16.9）
χ²（Z）值		0.986	0.143^a	0.706			4.958		0.442
P值		>0.999	0.705	>0.999			0.026		0.506
组别	TPOAb[例（%）]		¹³¹I治疗次数[M（P₂₅，P₇₅），次]	¹³¹I累积剂量[M（P₂₅，P₇₅），mCi]	首次¹³¹I治疗前s-Tg [M（P₂₅，P₇₅），μg/L]	首次¹³¹I治疗前TgAb [M（P₂₅，P₇₅），U/mL]
组别	阳性	阴性	¹³¹I治疗次数[M（P₂₅，P₇₅），次]	¹³¹I累积剂量[M（P₂₅，P₇₅），mCi]	首次¹³¹I治疗前s-Tg [M（P₂₅，P₇₅），μg/L]	首次¹³¹I治疗前TgAb [M（P₂₅，P₇₅），U/mL]
TgAb阳性组	11（37.9）	18（62.1）	2.0（2.0，4.0）	315.0（265.0，712.5）	235.80（27.32，3 960.00）	12.95（8.98，33.18）
TgAb阴性组	22（13.8）	138（86.2）	2.0（2.0，3.0）	300.0（270.0，400.0）	93.88（30.35，418.90）	0.17（0.10，0.20）
χ²（Z）值	4.356		0.005^a	0.023^a	3.277^a	50.502^a
P值	0.037		0.944	0.880	0.070	<0.001

Efficacy Analysis of ¹³¹I Therapy in Serum Thyroglobulin Antibody Positive Differentiated Thyroid Carcinoma with Distant Metastasis

¹³¹I治疗血清甲状腺球蛋白抗体阳性分化型甲状腺癌远处转移的疗效研究

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 20

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Yisheng, TANG Fubo, SUN Yaru, ZHONG Yuanming, LI Zhifei. Clinical Efficacy of Percutaneous Endoscopic Posterior Tranforaminal Lumbar Interbody Fusion Combined with Height Adjustable Titanium Fusion Cage in the Treatment of Lumbar Spondylolisthesis with Lumbar Spinal Stenosis [J]. Chinese General Practice, 2023, 26(35): 4464-4471.
[2]	CHEN Lulu, ZHANG Liping, LI Jingwen, DONG Wenjie, WU Xin'ai. Clinical Effect and Safety of PD-1 Inhibitors plus Fruquintinib as Later-line Treatment for Metastatic Colorectal Cancer [J]. Chinese General Practice, 2023, 26(18): 2262-2267.
[3]	Ziqiang HONG, Dacheng JIN, Xiangdou BAI, Baiqiang CUI, Yunjiu GOU. Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer [J]. Chinese General Practice, 2022, 25(27): 3435-3442.
[4]	Xiangliu OUYANG, Bei GAO, Yanbin WANG, Liyun LIU, Cheng GU, Lichun ZHENG. Ultrasonographic Analysis of Primary Thyroid Lymphoma [J]. Chinese General Practice, 2022, 25(15): 1869-1874.
[5]	Xin XIE, Yan CHEN, Zhixu HE, Pei HUANG, Qinghua CHEN. Recent Advances of the Wiskott-aldrich Syndrome Protein Family Members in Tumorigenesis and Progression [J]. Chinese General Practice, 2022, 25(14): 1779-1789.
[6]	SUN Lei，LI Mei. TSH Suppression Therapy May Affect Bone Health，How to Manage Differentiated Thyroid Cancer Scientifically？ [J]. Chinese General Practice, 2021, 24(8): 941-946.
[7]	MA Dan，YIN Xinbo，LIU Jiahui，FANG Qunyao，HE Qiu，XIONG Yu，GONG Fanghua. Different Medications for Preventing 131I-induced Salivary Gland Damage in Thyroid Cancer Patients：a Network Meta-analysis　 [J]. Chinese General Practice, 2021, 24(30): 3828-3836.
[8]	SONG Yuzhi，ZHEN Chanjun，BAI Wenwen，LI Bo，QIAO Xueying，ZHOU Zhiguo. Intracranial Failure Analysis in Patients with Brain Metastasis from Lung Adenocarcinoma Harboring Epidermal Growth Factor Receptor Mutation　 [J]. Chinese General Practice, 2021, 24(29): 3704-3710.
[9]	WEN Ya，LIU Jingjing，LIU Liping，YAN Xiaohui，LI Xiaoyu，XIN Yuwei，BI Yanjing. Differential Analysis of Ultrasonographic and Intraoperative Characteristics between Focal Subacute Granulomatous Thyroiditis and Papillary Thyroid Carcinoma　 [J]. Chinese General Practice, 2021, 24(12): 1512-1516.
[10]	XIE Xingwei，LIU Chunmei，LIU Shuxian，SHEN Hang，ZHANG Daolong，ZHONG Liping，KONG Lingwei. Postoperative Diagnosis and Treatment of One Case of Thyroid Cancer：a Biopsychosocial Perspective　 [J]. Chinese General Practice, 2020, 23(5): 623-628.
[11]	GAO Fengjuan，ZHAO Jie，HAN Chengcheng，LIU Juhong，HE Zhihong，WEN Xiuqin，XIE Yan，ZHANG Ming，YAO Jun，YE Jingming. General Practitioner Health Management of a Patient with Differentiated Thyroid Cancer: a Teaching Case Study　 [J]. Chinese General Practice, 2020, 23(32): 4141-4145.
[12]	HE Yu，YANG Xi，YAN Hong，WANG Shuaiqi. Value of Preablation Stimulated Thyroglobulin，Stimulated Thyroglobulin，and Thyroglobulin Reduction Index in Predicting Long-term Remission Status in Differentiated Thyroid Cancer Patients Treated with Thyroid Remnant Ablation with 131I　 [J]. Chinese General Practice, 2020, 23(30): 3798-3805.
[13]	ZHANG Yajun，GUO Xiaomin，JIANG Yufeng. Clinical Significance of Thyroid Hormones and Antibodies in Patients with Primary Biliary Cholangitis　 [J]. Chinese General Practice, 2019, 22(33): 4064-4068.
[14]	YANG Sen，ZHAO Huaxin，WANG Zhaoxin，GE Xuhua，LU Yuan，JIN hua，BO Xiaojie，ZHANG Hanzhi，MA Le，PAN Ying，YU Dehua. Efficacy of Cinobufacin Capsule Combined with Fentanyl Transdermal Patch in the Treatment of Moderate and Severe Cancer Pain with Bone Metastasis　 [J]. Chinese General Practice, 2019, 22(32): 3993-3996.
[15]	LU Na，RAN Xiaodan，LI Yongwei，YANG Yulian. Evaluation of the Value of FT4/FT3 and Thyroglobulin Combined with Thyroid Hormone Antibodies in the Diagnosis of Subacute Thyroiditis　 [J]. Chinese General Practice, 2019, 22(3): 361-365.